ARGX
argenx SE NASDAQ Listed May 18, 2017$787.17
Pre-mkt
$806.29
+3.08%
Mkt Cap $48.7B
52w Low $510.06
65.3% of range
52w High $934.62
50d MA $757.07
200d MA $783.91
P/E (TTM)
37.1x
EV/EBITDA
49.5x
P/B
6.6x
Debt/Equity
0.0x
ROE
—
P/FCF
61.1x
RSI (14)
—
ATR (14)
—
Beta
-0.09
50d MA
$757.07
200d MA
$783.91
Avg Volume
340.6K
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Laarderhoogtweg 25 · Amsterdam 1101EB · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | TNS | 5.79 | 14.25 | +146.1% | 787.31 | -0.0% | -0.7% | — | — | — | — | — |
| Oct 30, 2025 | TNS | 4.37 | 5.18 | +18.5% | 820.36 | +1.0% | -0.2% | +1.0% | +0.6% | +0.1% | +2.2% | — |
| May 8, 2025 | TNS | 0.98 | 2.58 | +163.3% | 569.12 | +0.1% | -3.4% | +2.0% | -3.3% | -1.9% | +5.5% | — |
| Mar 31, 2025 | TNS | — | 2.58 | — | 591.87 | +0.0% | -4.2% | +2.9% | +1.1% | -5.9% | -0.9% | — |
| Oct 31, 2024 | TNS | 0.10 | 1.39 | +1290.0% | 586.30 | +0.9% | +1.6% | -1.2% | +2.3% | -2.2% | +0.4% | — |
| Sep 30, 2024 | TNS | — | 1.39 | — | 542.08 | -0.3% | +1.0% | +0.5% | -1.3% | -2.4% | -1.4% | — |
| May 9, 2024 | TNS | -0.71 | -1.04 | -46.5% | 382.55 | +0.1% | -2.1% | -4.0% | -1.0% | +5.9% | -0.1% | — |
| Mar 31, 2024 | TNS | — | -1.04 | — | — | — | — | — | — | — | — | — |
| Oct 31, 2023 | TNS | -1.48 | -1.25 | +15.5% | 469.57 | +0.8% | +5.4% | -0.5% | +1.6% | -1.4% | +0.9% | — |
| Sep 30, 2023 | TNS | — | -1.25 | — | — | — | — | — | — | — | — | — |
| Jun 21, 2023 | TNS | — | 0.82 | — | 399.37 | -0.8% | +0.3% | -1.0% | -2.2% | -2.0% | +1.2% | — |
| May 4, 2023 | TNS | -2.34 | -0.52 | +77.8% | 395.41 | +1.1% | +2.2% | +0.5% | -1.1% | +0.2% | +1.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2 | Oppenheimer | Maintains | Outperform → Outperform | — | $743.12 | $735.46 | -1.0% | +0.4% | +0.2% | +2.3% | +2.6% | +2.0% |
| Mar 9 | Wedbush | Maintains | Outperform → Outperform | — | $717.80 | $715.73 | -0.3% | +3.1% | +0.3% | -2.0% | -2.6% | -1.2% |
| Feb 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $771.53 | $774.00 | +0.3% | -0.6% | -1.3% | -1.1% | +0.1% | -2.9% |
| Feb 27 | Citizens | Maintains | Market Outperform → Market Outperform | — | $771.53 | $774.00 | +0.3% | -0.6% | -1.3% | -1.1% | +0.1% | -2.9% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $771.53 | $774.00 | +0.3% | -0.6% | -1.3% | -1.1% | +0.1% | -2.9% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $771.53 | $774.00 | +0.3% | -0.6% | -1.3% | -1.1% | +0.1% | -2.9% |
| Feb 27 | Baird | Maintains | Neutral → Neutral | — | $771.53 | $774.00 | +0.3% | -0.6% | -1.3% | -1.1% | +0.1% | -2.9% |
| Feb 27 | RBC Capital | Maintains | Outperform → Outperform | — | $771.53 | $774.00 | +0.3% | -0.6% | -1.3% | -1.1% | +0.1% | -2.9% |
| Jan 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $800.01 | $785.53 | -1.8% | +1.2% | +0.8% | +1.3% | -1.5% | +2.3% |
| Jan 14 | Wedbush | Maintains | Outperform → Outperform | — | $810.51 | $809.26 | -0.2% | -1.4% | +1.7% | -1.6% | +1.2% | +0.8% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $822.94 | $826.67 | +0.5% | -3.3% | -0.9% | +1.0% | +1.8% | -1.4% |
| Jan 8 | Citigroup | Maintains | Buy → Buy | — | $822.94 | $826.67 | +0.5% | -3.3% | -0.9% | +1.0% | +1.8% | -1.4% |
| Dec 18 | Baird | Downgrade | Outperform → Neutral | — | $862.05 | $858.35 | -0.4% | -1.7% | +0.9% | -0.3% | -0.7% | +0.5% |
| Dec 17 | RBC Capital | Maintains | Outperform → Outperform | — | $851.42 | $865.33 | +1.6% | +1.2% | -1.7% | +0.9% | -0.3% | -0.7% |
| Dec 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $850.95 | $853.99 | +0.4% | +0.1% | +1.2% | -1.7% | +0.9% | -0.3% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $890.11 | $887.14 | -0.3% | -0.1% | -1.3% | -3.1% | +0.1% | +1.2% |
| Dec 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $890.11 | $887.14 | -0.3% | -0.1% | -1.3% | -3.1% | +0.1% | +1.2% |
| Dec 8 | JP Morgan | Maintains | Overweight → Overweight | — | $901.17 | $912.88 | +1.3% | -0.0% | -1.3% | +0.1% | -0.1% | -1.3% |
| Dec 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $921.80 | $926.47 | +0.5% | -0.6% | -1.6% | -0.0% | -1.3% | +0.1% |
| Nov 24 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $918.92 | $914.62 | -0.5% | -1.3% | +1.2% | -0.0% | -0.6% | -1.9% |
| Nov 17 | Citigroup | Maintains | Buy → Buy | — | $907.98 | $911.52 | +0.4% | +2.4% | -1.2% | -0.4% | +0.4% | +0.0% |
| Nov 14 | Wedbush | Maintains | Outperform → Outperform | — | $891.73 | $881.25 | -1.2% | +1.8% | +2.4% | -1.2% | -0.4% | +0.4% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $851.02 | $856.48 | +0.6% | +0.4% | +1.8% | +2.3% | +0.0% | +0.2% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $826.28 | $825.36 | -0.1% | +0.6% | +0.1% | +2.2% | +0.4% | +1.8% |
| Oct 31 | TD Cowen | Maintains | Buy → Buy | — | $820.36 | $828.85 | +1.0% | -0.2% | +1.0% | +0.6% | +0.1% | +2.2% |
| Oct 31 | Evercore ISI | Maintains | Outperform → Outperform | — | $820.36 | $828.85 | +1.0% | -0.2% | +1.0% | +0.6% | +0.1% | +2.2% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $820.36 | $828.85 | +1.0% | -0.2% | +1.0% | +0.6% | +0.1% | +2.2% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $820.36 | $828.85 | +1.0% | -0.2% | +1.0% | +0.6% | +0.1% | +2.2% |
| Oct 13 | Wedbush | Maintains | Outperform → Outperform | — | $796.92 | $796.73 | -0.0% | +0.3% | +1.7% | +0.3% | +2.7% | +0.8% |
| Oct 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $737.56 | $775.92 | +5.2% | +4.0% | +3.2% | +1.1% | -1.5% | +1.2% |
| Sep 18 | Guggenheim | Maintains | Buy → Buy | — | $734.35 | $731.47 | -0.4% | -0.4% | +0.7% | +0.4% | -0.8% | -0.6% |
| Sep 15 | Truist | Maintains | Buy → Buy | — | $756.38 | $757.99 | +0.2% | +0.1% | -0.6% | -2.4% | -0.4% | +0.7% |
| Sep 2 | BofA Securities | Maintains | Buy → Buy | — | $712.20 | $712.01 | -0.0% | -0.8% | +2.2% | +1.6% | +2.3% | +2.3% |
| Aug 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $677.32 | $698.26 | +3.1% | +4.5% | -0.0% | -0.5% | +1.2% | -0.8% |
| Aug 4 | JP Morgan | Maintains | Overweight → Overweight | — | $673.80 | $679.77 | +0.9% | +2.5% | -2.2% | -0.3% | -0.1% | -1.6% |
| Aug 1 | Guggenheim | Maintains | Buy → Buy | — | $670.33 | $672.58 | +0.3% | +0.5% | +2.5% | -2.2% | -0.3% | -0.1% |
| Aug 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $670.33 | $672.58 | +0.3% | +0.5% | +2.5% | -2.2% | -0.3% | -0.1% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $670.33 | $672.58 | +0.3% | +0.5% | +2.5% | -2.2% | -0.3% | -0.1% |
| Jul 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $598.89 | $688.38 | +14.9% | +11.9% | +0.5% | +2.5% | -2.2% | -0.3% |
| Jul 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $551.22 | $555.38 | +0.8% | -1.6% | +0.5% | -0.3% | +0.5% | -1.4% |
| Jun 24 | Wedbush | Maintains | Outperform → Outperform | — | $540.76 | $549.58 | +1.6% | +5.0% | -1.3% | -0.1% | +0.0% | -1.6% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $575.46 | $578.87 | +0.6% | -0.1% | +2.1% | -1.5% | -4.6% | -1.9% |
| Jun 11 | Wedbush | Maintains | Outperform → Outperform | — | $575.46 | $578.87 | +0.6% | -0.1% | +2.1% | -1.5% | -4.6% | -1.9% |
| Jun 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $583.62 | $586.80 | +0.5% | -1.4% | -0.1% | +2.1% | -1.5% | -4.6% |
| May 13 | Baird | Upgrade | Neutral → Outperform | — | $560.90 | $557.37 | -0.6% | -3.3% | -1.9% | +5.5% | +0.7% | +2.2% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $569.12 | $569.60 | +0.1% | -3.4% | +2.0% | -3.3% | -1.9% | +5.5% |
| May 9 | Citigroup | Maintains | Buy → Buy | — | $569.12 | $569.60 | +0.1% | -3.4% | +2.0% | -3.3% | -1.9% | +5.5% |
| May 9 | Guggenheim | Maintains | Buy → Buy | — | $569.12 | $569.60 | +0.1% | -3.4% | +2.0% | -3.3% | -1.9% | +5.5% |
| Apr 17 | Citigroup | Maintains | Buy → Buy | — | $587.59 | $590.90 | +0.6% | +1.5% | -0.1% | +0.7% | -0.9% | +1.0% |
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $605.38 | $600.30 | -0.8% | -2.9% | +1.5% | -0.1% | +0.7% | -0.9% |
No insider trades available.
No recent filings available.
Data updated apr 26, 2026 9:37am
· Source: massive.com